Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06466525 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06466525 · ClinicalTrials.gov record · last posted 2026-08-21

A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.

Name: A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. — clinical trial record (NCT06466525)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorLongevity Biotech Australia Pty Ltd (subsidiary)

Started2024-07-16

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.

Protocol amendment history 2 changes detected by DataLookout

2026-08-22

Primary completion pushed: 2025-10 → 2027-02

2026-08-22

Completion pushed: 2025-10 → 2027-02

Trial Details

NCT Number	NCT06466525
Lead Sponsor	Longevity Biotech Australia Pty Ltd (subsidiary)
Conditions	Parkinson Disease
Enrollment	64 participants
Start Date	2024-07-16
Primary Completion	2027-02 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2026-08-21